ITC Issues Ban on Infringing Photodynamic Therapy Imports
Published Date: 5/11/2026
Notice
Summary
The U.S. International Trade Commission found that some photodynamic therapy devices and related products imported by certain companies broke patent rules. To fix this, they’re blocking these products from entering the U.S. without permission and ordering the companies to stop selling them. This means affected businesses must act fast or face legal and financial consequences.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Limited Exclusion Order blocking imports
The Commission issued a Limited Exclusion Order (LEO) prohibiting the unlicensed entry into the United States of infringing photodynamic therapy systems, components, and pharmaceutical products that are manufactured by or on behalf of the named respondents or their affiliates. The determination was made by Commission vote on May 6, 2026 and applies to products found to infringe the asserted patents.
Cease-and-desist orders for named respondents
The Commission issued cease-and-desist orders (CDOs) against each named respondent — Biofrontera Inc.; Biofrontera Pharma GmbH; Biofrontera Bioscience GmbH; and Biofrontera AG — requiring them to stop selling the infringing photodynamic therapy systems, components, and related pharmaceutical products. The Commission terminated the investigation after issuing these orders following its May 6, 2026 vote.
Zero percent bond during Presidential review
The Commission set a bond of zero percent (0%) for any importations of the infringing products during the period of Presidential review, under 19 U.S.C. 1337(j). This means importers would not have to post a monetary bond for the covered products during that review period.
Orders suspended for '028 patent pending appeals
The Commission suspended the remedial orders as to U.S. Patent No. 11,697,028 (the '028 patent) in light of a Final Written Decision (FWD) from the Patent Trial and Appeal Board and pending any further action before the Board or potential appeals. The suspension applies while the Board and any appeals remain active.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10002 — Oil Country Tubular Goods From China; Determinations
The U.S. International Trade Commission decided to keep special taxes on oil country tubular goods from China because removing them could hurt American businesses soon. This means companies importing these steel pipes from China will still pay extra fees, protecting U.S. manufacturers. The decision was finalized in May 2026 and affects trade and prices going forward.
2026-09984 — Certain Preserved Mushrooms from Chile, China, India, and Indonesia; Scheduling of Expedited Five-Year Reviews
The U.S. International Trade Commission is speeding up its check on whether to keep or drop special duties on preserved mushrooms from Chile, China, India, and Indonesia. This affects mushroom importers and U.S. producers, with decisions expected soon to protect American businesses from unfair pricing. The review started on May 8, 2026, and could impact prices and trade rules.
2026-09664 — Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission just got a complaint about certain NAND and DRAM memory chips imported and sold in the U.S. Big tech companies like KIOXIA and SK hynix are involved, and the Commission wants your thoughts on how this might affect the public. This could lead to import bans or sales stops, so keep an eye out for changes that might shake up the tech market soon!
2026-09537 — Notice of Receipt of Complaint; Solicitation of Comments Relating to the Public Interest
The U.S. International Trade Commission got a complaint from Xockets, Inc. saying some big tech companies like NVIDIA, Microsoft, and Amazon might be selling certain GPU and data processing tech illegally in the U.S. The Commission wants your thoughts on how this could affect the public before deciding on possible bans or restrictions. This could lead to changes in what products are allowed and might impact sales during a 60-day review period.
2026-09531 — Crystalline Silicon Photovoltaic Cells, Whether or Not Assembled Into Modules, From India, Indonesia, and Laos; Scheduling of the Final Phase of Antidumping and Countervailing Duty Investigations
The U.S. is investigating whether solar panels and cells from India, Indonesia, and Laos are being unfairly priced or subsidized, which might hurt American solar businesses. This final review will decide if extra taxes should be added to these imports to protect U.S. companies. The investigation started on April 28, 2026, and could impact prices and trade soon.
2026-09445 — Non-Oriented Electrical Steel From China, Germany, Japan, South Korea, Sweden, and Taiwan; Determinations
The U.S. International Trade Commission decided to keep special taxes (called duties) on certain steel from China, Germany, Japan, South Korea, Sweden, and Taiwan. These taxes help protect American steel makers from unfair competition. If the taxes were removed, U.S. steel companies could get hurt again, so the duties will stay in place starting now.
Previous / Next Documents
Previous: 2026-09242 — Issuance of Priority Review Voucher; Rare Pediatric Disease Product; AVLAYAH (tividenofusp alfa-eknm)
The FDA just gave Denali Therapeutics a special priority review voucher for their rare pediatric disease drug AVLAYAH, approved in March 2026. This voucher speeds up the review of future medicines, helping kids with rare diseases get treatments faster. It’s a big win for patients, the company, and anyone watching rare disease drug development!
Next: 2026-09244 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Testing Communications On Medical Devices and Radiation-Emitting Products
The FDA is asking for public comments on their plan to keep testing how they communicate about medical devices and radiation products. This helps them make sure their messages reach patients, caregivers, and healthcare pros clearly and effectively. Comments are due by June 10, 2026, and this review won’t cost anyone extra but will improve important health info.